Addex to present at 10th International Meeting on Metabotropic Glutamate Receptors

0

Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.


Geneva, Switzerland, October 4, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering the discovery and development of drugs based on allosteric modulation, today announced that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Chemistry, will be present today at the 10th International Meeting on Metabotropic Glutamate Receptors (1 – 6 October 2021). Dr Paparin, Senior Manager – Chemistry, will also attend the conference.

In a first presentation, Dr Rocher will discuss recent developments in our understanding of the allosteric binding pocket of the mGlu2 receptor and the implications for drug discovery in the field of mGlu2 selective allosteric modulators. In a second presentation, Dr Lütjens will discuss the discovery and development of ADX71149, the mGlu2 positive allosteric modulator discovered in collaboration with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, currently in a study phase 2a in epilepsy. the patients.

In addition, Dr Lütjens and Dr Rocher will discuss the following preclinical programs, mGlu2 NAM for the treatment of mild neurocognitive disorders, mGlu3 PAM for the treatment of neurodegenerative disorders, mGlu4 PAM for the treatment of Parkinson’s disease and mGlu7 NAM for the treatment of -Traumatic stress disorder. More information on these programs can be found on our website under our pipeline section.

Management will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or at [email protected]

About Addex Therapeutics:

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of new orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecules or biologics. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins recognized as essential for therapeutic intervention. Addex’s leading drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease, in addition to the phase 2 clinical study for blepharospasm. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a phase 2a proof-of-concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates focusing on addiction. Ongoing preclinical programs with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and the American Depositary Shares representing its shares are listed on the NASDAQ Capital Market and trade under the symbol “ADXN” on each stock exchange.

Contact:

Addex Forward-looking statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, in particular with regard to the early initiation of clinical trials. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate “,” predict “,” project “,” potential “,” continue “,” target “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements contained in this press release are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to occur. differ materially from those expressed or implied by any forward-looking statement. the forward-looking statements contained in this press release, including, without limitation, uncertainties relating to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as in Market Conditions and Regulatory Review. All forward-looking statements contained in this press release represent Addex Therapeutics. ‘views only as of the date hereof and should not be construed as representing its views at any later date. Addex Therapeutics explicitly disclaims any obligation to update forward-looking statements.

Geneva, Switzerland, October 4, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering the discovery and development of drugs based on allosteric modulation, today announced that Dr Robert Lütjens, Head of Discovery – Biology and Dr Jean -Philippe Rocher, head of discovery – chemistry, present at the 10th international meeting on metabotropic glutamate receptors (1 – 6 October 2021).

In their presentation, which is scheduled for Monday, October 4, 2021, Dr Lütjens and Dr Rocher will discuss recent developments in the following preclinical programs: mGlu2 negative allosteric modulator (NAM) for the treatment of mild neurocognitive disorders, mGlu3 positive allosteric modulator (PAM) ) for the treatment of neurodegenerative disorders, mGlu4 PAM for the treatment of Parkinson’s disease and mGlu7 NAM for the treatment of post-traumatic stress disorder.

You can find more information about these programs on our website in the pipeline section.

The Addex team will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact us at [email protected]

On Addex Therapeutic:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of new orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecules or biologics. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins recognized as essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator, or NAM), is in a pivotal registration clinical trial for levodopa-induced dyskinesia in Parkinson’s disease (PD-LID Addex studies also the therapeutic use of dipraglurant in blepharospasm, a type of dystonia, for which a clinical trial was initiated in the third quarter of 2021. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof-of-concept clinical trial for the treatment of epilepsy. PLC has licensed Addex’s GABAB PAM program for drug candidate development with a focus on addiction. Ongoing preclinical programs with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative diseases. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares represent i Its shares are listed on the NASDAQ Capital Market and trade under the symbol “ADXN” on each stock exchange.

Contact:

Addex Forward-looking statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, in particular with regard to the early initiation of clinical trials. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate “,” predict “,” project “,” potential “,” continue “,” target “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements contained in this press release are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to occur. differ materially from those expressed or implied by any forward-looking statement. the forward-looking statements contained in this press release, including, without limitation, uncertainties relating to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as in Market Conditions and Regulatory Review. All forward-looking statements contained in this press release represent Addex Therapeutics. ‘views only as of the date hereof and should not be construed as representing its views at any later date. Addex Therapeutics explicitly disclaims any obligation to update forward-looking statements.

Main logo

Source: Addex Therapeutics


Source link

Share.

Leave A Reply